Although GM-CSF has been explored as a means to restore immune competence in sepsis, its early use may exacerbate hyperinflammation, whereas its deficiency may worsen immunoparesis, indicating that its therapeutic utility is likely context-dependent and influenced by individual immune profiles (9, 56, 57). The gene discussed is CSF2; the disease is Sepsis.